| 6.18 0.18 (3%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.83 | 1-year : | 9.15 |
| Resists | First : | 6.71 | Second : | 7.83 |
| Pivot price | 6.11  |
|||
| Supports | First : | 5.54 | Second : | 4.82 |
| MAs | MA(5) : | 6.08 |
MA(20) : | 6.03 |
| MA(100) : | 6.7 |
MA(250) : | 7.16 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 38.1 |
D(3) : | 40 |
| RSI | RSI(14): 57 |
|||
| 52-week | High : | 9.55 | Low : | 4.3 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ DERM ] has closed below upper band by 33.1%. Bollinger Bands are 75.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.21 - 6.24 | 6.24 - 6.25 |
| Low: | 5.83 - 5.86 | 5.86 - 5.88 |
| Close: | 6.14 - 6.18 | 6.18 - 6.22 |
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
Wed, 03 Jun 2026
How The Journey Medical (DERM) Investment Narrative Is Evolving With An Unchanged Valuation Target - Yahoo Finance
Fri, 22 May 2026
Number of shareholders of Journey Medical Corporation – NASDAQ:DERM - TradingView
Tue, 19 May 2026
Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference - GlobeNewswire
Wed, 13 May 2026
Journey Medical (Nasdaq: DERM) posts 21% Q1 2026 revenue growth - Stock Titan
Wed, 13 May 2026
Rosacea pill Emrosi powers Journey Medical’s 21% Q1 revenue jump - Stock Titan
Wed, 13 May 2026
Journey Medical (DERM) Q1 2026 Earnings Transcript - The Motley Fool
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 22 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 32.3 (%) |
| Held by Institutions | 55.6 (%) |
| Shares Short | 3,470 (K) |
| Shares Short P.Month | 3,720 (K) |
| EPS | -0.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.12 |
| Profit Margin | -14.9 % |
| Operating Margin | -9.4 % |
| Return on Assets (ttm) | -4.5 % |
| Return on Equity (ttm) | -36.7 % |
| Qtrly Rev. Growth | 21.5 % |
| Gross Profit (p.s.) | 1.96 |
| Sales Per Share | 3 |
| EBITDA (p.s.) | -0.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -16.71 |
| PEG Ratio | 0 |
| Price to Book value | 5.46 |
| Price to Sales | 2.05 |
| Price to Cash Flow | -19.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|